Surgery for Pancreatic Cancer With Oligo-Metastasis

Surgery/Destruction for Stage IV Pancreatic Cancer With Oligo-Metastatic Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04196816

Acronym

SPaM

Enrollment

200

Registered

2019-12-12

Start date

2020-01-01

Completion date

2020-12-01

Last updated

2020-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer, Pancreatic Surgery

Keywords

Surgery, Metastasis surgery, Survival, Multimodal treatment, Stage IV

Brief summary

Pancreatic cancer is increasing in incidence and will be the second leading cause of cancer-related deaths in 2030 in the West. Only 10 to 15% of patients are eligible for curative resection with long-term survival rarely exceeding 20% at 5 years. The management of metastatic or recurrent diseases can not, unfortunately, be recommended to date because of limited data available (INCA 2019). However, recent, low-strength publications have reported encouraging results on the long-term survival of stage IV or recurrent patients. The aim of the present retrospective cohort study is to analyze results of surgery/destruction of metastatic synchronous or metachronous disease or local recurrence in patients with stage IV pancreatic cancer

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 95 Years

Healthy volunteers

Inclusion criteria

\- Patients who had resection or destruction of one or more synchronous or metachronous metastases or local recurrence of pancreatic adenocarcinoma Details: * synchronous lesions, metachrones can be included * all distant lesions (hepatic, pulmonary) can be included * documented lymph node involvement after analysis of the specimen (hepatic hilum, mesenteric root, retroperitoneal or inter-aortic-cellar) can be included * patients with local recurrence who underwent surgical treatment

Exclusion criteria

\- Patient who reject the study protocol

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	3 years	Overall survival at 3 years (percentage of patients alive). Overall survival (OS) (time from diagnosis until death, regardless of cause)

Secondary

Measure	Time frame	Description
Progression-free survival	3 years	Progression-free survival (percentage of patients without recurrence) at 3 years. Progression-free survival (PFS) (time from diagnosis to time of first radiological evidence of local, regional, or distant relapse, or death due to any cause)

Countries

France

Outcome results